EXOSC8

Across TCGA pan-cancer cohorts, EXOSC8 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EXOSC8 data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EXOSC8 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EXOSC8 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where EXOSC8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.426	1.000	.004	17	view →
PDAC	OS	Quartile	III,IV	0.446	0.938	.034	4	view →
HNSC	DFS	Median	III,IV	0.902	0.993	.019	1	view →
LUAD	DFS	Median	II,III,IV	0.936	0.734	.021	1	view →
LSCC	OS	Quartile	II,III,IV	0.922	0.619	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EXOSC8–CCRCC (DFS)

Open the CCRCC breakdown →